医学创新论坛第81期
时间：2025年9月10日（周三）下午16:00
地点：首都医科大学基础科研楼北楼二层多功能厅
主持人：
孙少聪
首都医学科学创新中心
报告人：
林欣
教授
清华大学医学院
报告题目：
Developing TCR-based Chimeric Antigen Receptor STAR for Immunotherapy
摘要：
Chimeric antigen receptor T (CAR-T) cell therapies for B cell malignancies demonstrate high response rate and durable disease control. However, in the case of solid tumors, CAR-T cells have not shown the promising effect. In our study, we construct a two-chain chimeric receptor, termed as Synthetic T Cell Receptor and Antigen Receptor (STAR), which incorporates antigen-recognition domain of antibody and engages entire CD3 signaling machinery of T cell receptor (TCR). STAR triggers strong and sensitive TCR-like signaling upon antigen stimulation. We found that STAR combines the advantage of CAR and TCR, which can be used to target both cell surface antigen and MHC-presented neoantigen for cancer cells. Thus, STAR-T cells provide a powerful approach to treat tumors and autoimmune diseases.
代表性论文：
1. Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, Lin S, Zhao X, Lin X. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021 Mar 24; 13(586): eabb5191.
2. Huang D, Li Y, Rui W, Sun K, Zhou Z, Lv X, Yu L, Chen J, Zhou J, Liu V, Wang J, Lan X, Fu YX, Zhao X, Lin X. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 2024 Nov 26; 43(11): 114949.
3. Yu L, Zhou Z, Yu H, Liu Y, Huang D, Wang J, Lin X. Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy. Mol Ther. 2025 Apr 2; 33(4): 1552-1565.
北京市丰台区右安门外西头条10号
010-86738999
cimr@cimrbj.ac.cn
En
